Good evening :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Nureca Ltd

NURECA

Nureca Ltd

NURECA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹285 cr, stock is ranked 2,246
High RiskStock is 3.08x as volatile as Nifty
282.401.22% (-3.50)
282.401.22% (-3.50)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹285 cr, stock is ranked 2,246
High RiskStock is 3.08x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹285 cr, stock is ranked 2,246
High RiskStock is 3.08x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-101.621.48—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.926.650.51%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Nureca Ltd is engaged in the marketing of home healthcare & wellness products

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 10.57%, vs industry avg of 9.03%

Constant Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share stayed at 0.03%

Loading...

Financial YearFY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue216.2761.9999.49216.27263.25118.43102.44104.41
Raw Materialssubtract151.9150.1667.49120.01159.5544.7656.23104.22
Power & Fuel Costsubtract0.020.040.010.160.200.13
Employee Costsubtract0.893.164.589.9116.0612.20
Selling & Administrative Expensessubtract11.1219.6644.8151.7130.3424.91
Operating & Other expensessubtract-9.35-0.61-17.50-21.2934.978.67
Depreciation/Amortizationsubtract0.420.060.370.421.482.392.362.47
Interest & Other Itemssubtract1.600.240.771.600.740.450.490.71
Taxes & Other Itemssubtract15.962.612.2215.9616.02-2.49-0.75-0.17
EPS62.04891.43912.8692.1144.97-8.25-1.80-2.82
DPS—0.000.002.003.000.000.000.00
Payout ratio0.000.000.000.020.070.000.000.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 10PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Nureca Ltd-159.201.48—
Sun Pharmaceutical Industries Ltd45.126.440.75%
Cipla Ltd28.854.440.88%
Torrent Pharmaceuticals Ltd69.1016.690.83%

Price Comparison

Compare NURECA with any stock or ETF
Compare NURECA with any stock or ETF
NURECA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Decreased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 2.38%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding63.77%0.00%0.04%0.69%35.50%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.10%0.10%0.07%0.07%0.07%0.69%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateFeb 24, 2022

Interim
Interim | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Feb 24, 2022

Cash Dividend

Ex DateEx DateSep 21, 2021

Final
Final | Div/Share: ₹2.00

Dividend/Share

₹2.00

Ex DateEx Date

Sep 21, 2021

News & Opinions
Earnings
Nureca reports consolidated net loss of Rs 0.48 crore in the September 2024 quarter

Net loss of Nureca reported to Rs 0.48 crore in the quarter ended September 2024 as against net profit of Rs 2.89 crore during the previous quarter ended September 2023. Sales declined 0.51% to Rs 31.19 crore in the quarter ended September 2024 as against Rs 31.35 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales31.1931.35 -1 OPM %-7.574.40 - PBDT0.554.50 -88 PBT-0.083.91 PL NP-0.482.89 PL Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Nureca to declare Quarterly Result

Nureca will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Nureca reports consolidated net profit of Rs 1.66 crore in the June 2024 quarter

4 months agoBusiness Standard
Earnings
Nureca reports consolidated net profit of Rs 1.66 crore in the June 2024 quarter

Net profit of Nureca reported to Rs 1.66 crore in the quarter ended June 2024 as against net loss of Rs 0.71 crore during the previous quarter ended June 2023. Sales declined 4.52% to Rs 20.27 crore in the quarter ended June 2024 as against Rs 21.23 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales20.2721.23 -5 OPM %-11.64-13.66 - PBDT3.28-0.35 LP PBT2.62-0.93 LP NP1.66-0.71 LP Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Nureca announces board meeting date

Nureca will hold a meeting of the Board of Directors of the Company on 5 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Nureca Standalone December 2022 Net Sales at Rs 27.84 crore, down 42.1% Y-o-Y

1 year agoMoneycontrol

Nureca Consolidated December 2022 Net Sales at Rs 27.79 crore, down 42.2% Y-o-Y

1 year agoMoneycontrol

Nureca consolidated net profit declines 93.66% in the December 2022 quarter

1 year agoBusiness Standard

Sensex shed 236 pts, Nifty at 18,028; Nureca zooms 20%, Coforge and Paytm rise 4% each

1 year agoBusiness Today

Nureca shares rebound 25% from day’s low amid heavy volumes, up 17%

1 year agoBusiness Today